Latest Administration News

DevEx Resources is gearing up for a major uranium drilling campaign in 2026 after expanding its Northern Territory footprint and securing nearly $39 million in fresh capital. Soil anomalies at Murphy West and strategic licence acquisitions set the stage for exploration in the McArthur Basin.

Santana Minerals advanced its Bendigo-Ophir Gold Project in New Zealand with a confirmed consent decision date, major equipment agreements, and a substantial capital raise, setting the stage for development.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Nordic Resources (ASX:NNL) has completed its assay reporting for the 2025 Kopsa drilling program, revealing a new higher-grade stockwork zone and multiple mineralised extensions outside current resource boundaries. Drilling has resumed at Kopsa and Kiimala, with metallurgical testing underway and an updated resource estimate due in Q3 2026.

NT Minerals Limited aims to raise up to $968,722 through a pro-rata entitlement offer and complete the acquisition of Slipstream Paynes Find, a move critical to meeting ASX reinstatement conditions and funding exploration in Western Australia.

Cooper Metals has completed all regulatory approvals for a ~1,400m RC drill program at Ardmore North, targeting Q2 2026 commencement. The company also executed a strategic asset swap to acquire the Pyramid Gold Project, backed by a nearly $1 million placement.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.